Mapping the European cancer research landscape: An evidence base for national and Pan-European research and funding

摘要: Abstract Background Cancer research is among the most active biomedical domains for European Union (EU). However, little quantitative empirical evidence available to guide decisions on choice of disease site study, specific domain focus or allocation resources. To inform national/supranational cancer policy, high-resolution intelligence needed. Methods We performed a bibliometric analysis papers in Web Science from 2002 2013 quantify activity each 28 EU Member States, along with Iceland, Norway and Switzerland (EUR31), which sites/research they addressed, their sources financial support (2009–2013). Findings EUR31 correlated well national Gross Domestic Products (r2 = 0.94). certain sites (lung, oesophagus pancreas) were under-researched relative burden, whereas central nervous system blood cancers were more generously supported than burden would warrant. An indicated paucity radiotherapy (5%), palliative care (1.2%) quality life (0.5%). funding 2012–2013 amounted ∼€7.6 billion came diverse sources, especially western Europe/Scandinavia, where nine countries charitable sector outspent government but not Eastern Europe barely exists. Interpretation Several need increase outputs substantially, and/or alter portfolios better match growing (and changing) burden. More co-ordination agencies required, so that resources can be attuned align activities gaps perceived clinical needs. In Europe, needs developed, both public patient advocacy have an role research.